GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CSL Ltd (ASX:CSL) » Definitions » Shiller PE Ratio

CSL (ASX:CSL) Shiller PE Ratio : 45.67 (As of May. 01, 2024)


View and export this data going back to 1994. Start your Free Trial

What is CSL Shiller PE Ratio?

As of today (2024-05-01), CSL's current share price is A$274.49. CSL's E10 for the fiscal year that ended in Jun23 was A$6.01. CSL's Shiller PE Ratio for today is 45.67.

The historical rank and industry rank for CSL's Shiller PE Ratio or its related term are showing as below:

ASX:CSL' s Shiller PE Ratio Range Over the Past 10 Years
Min: 35.92   Med: 53.51   Max: 94.49
Current: 45.51

During the past 13 years, CSL's highest Shiller PE Ratio was 94.49. The lowest was 35.92. And the median was 53.51.

ASX:CSL's Shiller PE Ratio is ranked worse than
62.67% of 150 companies
in the Biotechnology industry
Industry Median: 34.975 vs ASX:CSL: 45.51

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

CSL's adjusted earnings per share data of for the fiscal year that ended in Jun23 was A$6.750. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is A$6.01 for the trailing ten years ended in Jun23.

Shiller PE for Stocks: The True Measure of Stock Valuation


CSL Shiller PE Ratio Historical Data

The historical data trend for CSL's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CSL Shiller PE Ratio Chart

CSL Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 60.43 71.86 61.73 50.35 46.19

CSL Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 50.35 - 46.19 -

Competitive Comparison of CSL's Shiller PE Ratio

For the Biotechnology subindustry, CSL's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CSL's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CSL's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where CSL's Shiller PE Ratio falls into.



CSL Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

CSL's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=274.49/6.01
=45.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CSL's E10 for the fiscal year that ended in Jun23 is calculated as:

For example, CSL's adjusted earnings per share data for the fiscal year that ended in Jun23 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun23 (Change)*Current CPI (Jun23)
=6.75/124.1700*124.1700
=6.750

Current CPI (Jun23) = 124.1700.

CSL Annual Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 2.874 98.352 3.628
201506 3.788 99.838 4.711
201606 3.625 100.859 4.463
201706 3.875 102.809 4.680
201806 5.081 104.945 6.012
201906 6.085 106.617 7.087
202006 6.687 106.246 7.815
202106 6.815 110.332 7.670
202206 6.830 117.112 7.242
202306 6.750 124.170 6.750

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


CSL  (ASX:CSL) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


CSL Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of CSL's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


CSL (ASX:CSL) Business Description

Traded in Other Exchanges
Address
655 Elizabeth Street, Melbourne, VIC, AUS, 3000
CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. Seqirus is now the world's second largest influenza vaccination business and was acquired in fiscal 2015. CSL has a strong R&D track record, and the product portfolio and pipeline include non-plasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.